Novo Nordisk commits $200 million to diabetes programmes
Key points
- Novo Nordisk (NYSE:NVO) committed US$200 million to the World Diabetes Foundation to support diabetes prevention and care.
- The commitment covers 2027–2036, with funding directed towards low- and middle-income countries.
- The initiative aims to strengthen local healthcare systems, expand access to diabetes services and improve support for underserved communities.
Novo Nordisk (NYSE:NVO) committed US$200 million to the World Diabetes Foundation over 10 years, from 2027 to 2036, to expand diabetes prevention and care in low- and middle-income countries.
The commitment will support programmes that integrate diabetes prevention and treatment into local health services, with a focus on communities facing limited access to healthcare.
The company said the funding reflects its continued commitment to improving diabetes prevention and care worldwide.
The investment will support initiatives aimed at strengthening local healthcare services and improving access to diabetes prevention, diagnosis and treatment, particularly among underserved populations.
The World Diabetes Foundation works with partners to improve diabetes prevention and care, particularly in countries with limited healthcare resources.
Novo Nordisk develops medicines for diabetes, obesity and other chronic diseases, with its business focused on pharmaceutical research, treatment development and expanding access to healthcare.
Frequently asked questions
More from United States
UCLOUDLINK revenue improves 1.1% to $21.4 million
Houlihan Lokey acquires Vicente & Partners to expand consumer advisory
Oil prices rebound as Hormuz shipping risks persist
Axalta and AkzoNobel target early 2027 merger completion
ITG revenue jumps 49% to $461.5 million
Gap authorizes $0.175 fourth-quarter dividend
